Dale K. Yu

546 total citations
24 papers, 436 citations indexed

About

Dale K. Yu is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Dale K. Yu has authored 24 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Dale K. Yu's work include Antibiotics Pharmacokinetics and Efficacy (5 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Dale K. Yu is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (5 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Dale K. Yu collaborates with scholars based in United States and Ireland. Dale K. Yu's co-authors include Ronald J. Sawchuk, Dennis H. Giesing, William F. Elmquist, Scott J. Weir, Vijay O. Bhargava, Roger Williams, Emil T. Lin, Leslie Z. Benet, Diane D‐S. Tang‐Liu and Zhi‐Ling Yu and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Clinical Chemistry and The American Journal of Gastroenterology.

In The Last Decade

Dale K. Yu

23 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dale K. Yu United States 12 148 106 95 70 59 24 436
Rosario Calvo Spain 12 100 0.7× 128 1.2× 93 1.0× 90 1.3× 70 1.2× 30 470
Jean Spénard Canada 15 95 0.6× 49 0.5× 62 0.7× 51 0.7× 69 1.2× 45 971
David B. Haughey United States 15 80 0.5× 86 0.8× 120 1.3× 128 1.8× 123 2.1× 34 611
Vijay O. Bhargava United States 15 100 0.7× 81 0.8× 96 1.0× 155 2.2× 44 0.7× 35 480
F. Follath Switzerland 13 90 0.6× 114 1.1× 155 1.6× 101 1.4× 72 1.2× 17 535
Ann Pariente‐Khayat France 11 58 0.4× 158 1.5× 129 1.4× 108 1.5× 39 0.7× 17 428
James J. Ferry United States 17 68 0.5× 66 0.6× 146 1.5× 80 1.1× 93 1.6× 37 775
Adnan El‐Yazigi Saudi Arabia 15 97 0.7× 64 0.6× 72 0.8× 110 1.6× 94 1.6× 60 597
Elena Suárez Spain 14 118 0.8× 148 1.4× 98 1.0× 96 1.4× 98 1.7× 59 659
Reinhard Ding Germany 11 139 0.9× 109 1.0× 88 0.9× 35 0.5× 57 1.0× 13 403

Countries citing papers authored by Dale K. Yu

Since Specialization
Citations

This map shows the geographic impact of Dale K. Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dale K. Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dale K. Yu more than expected).

Fields of papers citing papers by Dale K. Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dale K. Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dale K. Yu. The network helps show where Dale K. Yu may publish in the future.

Co-authorship network of co-authors of Dale K. Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Dale K. Yu. A scholar is included among the top collaborators of Dale K. Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dale K. Yu. Dale K. Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oefelein, Michael G., et al.. (2013). Effect of Concomitant Administration of Trospium Chloride Extended Release on the Steady-State Pharmacokinetics of Metformin in Healthy Adults. Clinical Drug Investigation. 33(2). 123–131. 16 indexed citations
2.
Yu, Dale K.. (2011). Translational research: current status, challenges and future strategies.. PubMed. 3(5). 422–33. 19 indexed citations
3.
Attar, Mayssa, et al.. (2005). Disposition and Biotransformation of the Acetylenic Retinoid Tazarotene in Humans. Journal of Pharmaceutical Sciences. 94(10). 2246–2255. 12 indexed citations
4.
Yu, Zhi‐Ling, Dale K. Yu, Patricia Walker, & Diane D‐S. Tang‐Liu. (2004). Tazarotene Does Not Affect the Pharmacokinetics and Efficacy of a Norethindrone/Ethinylestradiol Oral Contraceptive. Clinical Pharmacokinetics. 43(10). 673–684. 3 indexed citations
5.
Yu, Zhi‐Ling, John Sefton, Deborah A. Lew‐Kaya, et al.. (2003). Pharmacokinetics of Tazarotene Cream 0.1% After a Single Dose and After Repeat Topical Applications at Clinical or Exaggerated Application Rates in Patients with Acne Vulgaris or Photodamaged Skin. Clinical Pharmacokinetics. 42(10). 921–929. 8 indexed citations
6.
Tang–Liu, D., et al.. (2002). Long-term Systemic Exposure Of Lumigan In Patients With Glaucoma Or Ocular Hypertension. Investigative Ophthalmology & Visual Science. 43(13). 4108–4108. 3 indexed citations
7.
Madhu, Cherukury, et al.. (2002). Systemic Pharmacokinetics of Bimatoprost 0.03% Solution Following Once Daily Ocular Dosing In Normal, Healthy Subjects. Investigative Ophthalmology & Visual Science. 43(13). 1085–1085. 2 indexed citations
8.
Yu, Dale K.. (1999). The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions. The Journal of Clinical Pharmacology. 39(12). 1203–1211. 161 indexed citations
9.
Mahmood, Iftekhar, et al.. (1997). A Limited Sampling Method for the Estimation of Vigabatrin Maximum Plasma Concentration and Area Under the Curve. Therapeutic Drug Monitoring. 19(1). 79–82. 9 indexed citations
10.
Stoltz, M., et al.. (1997). Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16 455A). Biopharmaceutics & Drug Disposition. 18(7). 645–648. 21 indexed citations
11.
Yu, Dale K., Vijay O. Bhargava, & Scott J. Weir. (1997). Selection of Doses for Phase II Clinical Trials Based on Pharmacokinetic Variability Consideration. The Journal of Clinical Pharmacology. 37(8). 673–678. 1 indexed citations
12.
Yu, Dale K., Earl Nordbrock, Eric Lewis, et al.. (1995). Population pharmacokinetics of teicoplanin in patients with endocarditis. Journal of Pharmacokinetics and Biopharmaceutics. 23(1). 25–39. 15 indexed citations
13.
Yu, Dale K., et al.. (1995). Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man. European Journal of Clinical Pharmacology. 48-48(3-4). 273–7. 19 indexed citations
14.
Yu, Dale K., et al.. (1994). A comparison of population and standard two‐stage pharmacokinetic analyses of vigabatrin data. Biopharmaceutics & Drug Disposition. 15(6). 473–484. 8 indexed citations
15.
Yu, Dale K., et al.. (1991). Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. Biopharmaceutics & Drug Disposition. 12(7). 515–523. 6 indexed citations
16.
Yu, Dale K., et al.. (1990). Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. Clinical Pharmacology & Therapeutics. 48(1). 26–33. 29 indexed citations
17.
Yu, Dale K., Dennis H. Giesing, Roger Williams, Leslie Z. Benet, & Emil T. Lin. (1988). Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. Biopharmaceutics & Drug Disposition. 9(6). 557–565. 27 indexed citations
18.
Yu, Dale K., et al.. (1987). Pharmacokinetics of propylene glycol in the rabbit. Journal of Pharmacokinetics and Biopharmaceutics. 15(5). 453–471. 11 indexed citations
19.
Yu, Dale K., et al.. (1986). Pharmacokinetics of Dothiepin in Humans: A Single Dose Dose–Proportionality Study. Journal of Pharmaceutical Sciences. 75(6). 582–585. 10 indexed citations
20.
Yu, Dale K. & Ronald J. Sawchuk. (1983). Gas-liquid chromatographic determination of propylene glycol in plasma and urine.. Clinical Chemistry. 29(12). 2088–2090. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosario Calvo Breakdown of academic impact, for papers by Jean Spénard Breakdown of academic impact, for papers by David B. Haughey Breakdown of academic impact, for papers by Vijay O. Bhargava Breakdown of academic impact, for papers by F. Follath Breakdown of academic impact, for papers by Ann Pariente‐Khayat Breakdown of academic impact, for papers by James J. Ferry Breakdown of academic impact, for papers by Adnan El‐Yazigi Breakdown of academic impact, for papers by Elena Suárez Breakdown of academic impact, for papers by Reinhard Ding
Rankless by CCL
2026